Hims & Hers Health (HIMS)
(Delayed Data from NYSE)
$50.89 USD
-3.07 (-5.69%)
Updated Sep 16, 2025 03:59 PM ET
After-Market: $50.35 -0.54 (-1.06%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HIMS 50.89 -3.07(-5.69%)
Will HIMS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HIMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HIMS
Hims & Hers Expands AI and Technology Focus to Advance Digital Care
Company News for Sep 16, 2025
HIMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: Here's Why
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Other News for HIMS
Hims & Hers Stock (HIMS) Slumps as FDA Slams Its ‘False’ Weight Loss Drug Products
Trump announces $15B libel suit against New York Times: Morning Buzz
Trump announces $15B libel suit against New York Times: Morning Buzz
HIMS Stock Dips After FDA Warning on Marketing Claims
Trump announces $15 libel suit against New York Times: Morning Buzz